Integrated BioTherapeutics

8 articles about Integrated BioTherapeutics

• Integral Molecular and Integrated BioTherapeutics Collaborate to Engineer Broadly Protective Ebolavirus Vaccines

  11/2/2021

  A collaboration between Integral Molecular and Integrated BioTherapeutics, two biotechnology companies with deep expertise in virology, has resulted in engineered proteins that may enable next-generation vaccines with broad protection against Ebola and related viruses.

• Integrated Biotherapeutics Partners With CARB-X the First Toxoid Based Multivalent Vaccine for Methicillin-Resistant Staphylococcus Aureus

  11/2/2017

  Integrated BioTherapeutics announced today that is has been awarded up to $168,000, with the possibility of up to $8.3M more based on the achievement of milestones, to develop the first entirely toxoid-based multivalent vaccine for the prevention of MRSA.

• Integrated BioTherapeutics, In Collaboration With The Scripps Research Institute, Receives NIH Funding To Develop A Rationally Designed Pan-Ebolavirus Vaccine

  8/2/2017

• Integrated BioTherapeutics Release: Immunization Elicited Antibody Shows Universal Protection Against Multiple Ebolaviruses

  5/18/2017

• Integral Molecular, Inc. And Integrated BioTherapeutics Initiate Collaboration For Virus Vaccine Discovery

  3/3/2017

• Integrated BioTherapeutics Announces Licensing Agreement With Emergent BioSolutions For Development Of Equine Immunoglobulin Therapeutics For Filovirus Infections

  11/15/2016

• Chembio Diagnostics, Inc. Partners With Integrated BioTherapeutics To Develop Point-Of-Care Diagnostic Tests For Ebola And Febrile Illness

  10/27/2014

• Integrated BioTherapeutics Release: New Bioterrorism Vaccine Gets First Test In Humans

  2/27/2013